LCM
PVLA icon

Lynx1 Capital Management’s Palvella Therapeutics PVLA Stock Holding History

Lynx1 Capital Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-37,436
Closed -$621K – 24
2024
Q3 		$621K Sell
37,436
-6,063
-14% -$88.6K 0.22% 12
2024
Q2 		$427K Sell
43,499
-66,241
-60% -$747K 0.15% 13
2024
Q1 		$1.61M Sell
109,740
-12,458
-10% -$173K 0.41% 14
2023
Q4 		$1.78M Hold
122,198
– – 0.7% 12
2023
Q3 		$2.91M Hold
122,198
– – 1.93% 9
2023
Q2 		$1.62M Buy
122,198
+33,852
+38% +$2.05M 1.06% 11
2023
Q1 		$6.9M Buy
88,346
+17,989
+26% +$2.08M 5.75% 6
2022
Q4 		$5.85M Buy
70,357
+26,418
+60% +$2.12M 5.06% 7
2022
Q3 		$4.04M Buy
43,939
+3,647
+9% +$470K 3.65% 8
2022
Q2 		$6.03M Buy
40,292
+26,088
+184% +$4.76M 5.14% 7
2022
Q1 		$3.44M Buy
14,204
+9,413
+196% +$2.47M 3.2% 10
2021
Q4 		$1.45M Buy
+4,791
New +$1.53M 1.26% 9

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Lynx1 Capital Management's PVLA Position: Q4 2024 in Review

Lynx1 Capital Management sold out of Palvella Therapeutics (PVLA) in Q4 2024, closing a stake of 37,436 shares — an estimated $621K sold.

Lynx1 Capital Management first reported a position in PVLA in Q4 2021 and held it in 12 quarters. The position peaked at $6.9M in Q1 2023. 33 funds tracked by Wall St. Rank hold PVLA as of Q4 2024.

  • Lynx1 Capital Management reported no remaining Palvella Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Lynx1 Capital Management sold 37,436 Palvella Therapeutics shares in Q4 2024, an estimated $621K.
  • Lynx1 Capital Management first reported a position in Palvella Therapeutics in Q4 2021 and held it in 12 quarters.
  • Lynx1 Capital Management's Palvella Therapeutics position peaked at $6.9M in Q1 2023.
  • 33 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q4 2024.

Based on Lynx1 Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.